SQUAWK/NEWS
Menu
Live News EARNINGS ARTICLE L impact

Eaton Corp Q2 2026 Earnings

Adj EPS $3.15 (est $3.08) - Net Sales $8.5B (est $8.13B) - Aerospace Net Sales $1.2B (est $1.23B) - Electrical Global Net Sales $2.5B (est $2.24B) - Electrical Americas Net Sales $3.95b (est $3.82b) - Sees Q3 Organic Rev. +13.5% To +15.5% (est +10.6%) - Sees Q3 Adj EPS $3.46 To $3.56 (est $3.50) - Sees FY Organic Rev. +11% To +13% (est +12%)

Story updates

10:38:35 AM UTC
SquawkNews
EATON CORP Q2 2026 EARNINGS: ADJ EPS $3.15 (EST $3.08) || NET SALES $8.5B (EST $8.13B) || AEROSPACE NET SALES $1.2B (EST $1.23B) || ELECTRICAL GLOBAL NET SALES $2.5B (EST $2.24B) || ELECTRICAL AMERICAS NET SALES $3.95B (EST $3.82B) || SEES Q3 ORGANIC REV. +13.5% TO +15.5% (EST +10.6%) || SEES Q3 ADJ EPS $3.46 TO $3.56 (EST $3.50) || SEES FY ORGANIC REV. +11% TO +13% (EST +12%)
10:41:01 AM UTC
SquawkNews
Adj EPS $4.30 (est $3.46) Adj. EBITDA $2.1B (est $1.79B) Sales And Other Oper Rev $9.18B (est $8.94B)
10:47:09 AM UTC
SquawkNews
Eaton Corp Q2 2026 Earnings
10:58:17 AM UTC
SquawkNews
Adj EPS 99C (est 95C) - Net Sales $5.36B (est $5.35B) - Sees FY Net Sales +2% To +6% - Sees FY Organic Sales +1% To +4% (est +2.82%)
11:08:17 AM UTC
SquawkNews
Colgate-Palmolive Q2 2026 Earnings
11:08:28 AM UTC
SquawkNews
Rev. $145M (est $103.5M) - Loss/SHR $1.97 Vs. Loss/SHR $2.13 Y/Y - Total Oper Expenses $960M (est $921.8M) - Cash & Cash Equivalents $1.72B (est $1.34B) - R&D Expenses $651M (est $671.7M) - Expects C55% Of H2 Rev To Be Recognized In Q3 - Sees FY Rev Growth Of 10% - Sees FY R&D Expenses About $2.9B, Saw About $3B - Still Sees FY CAPEX $200M TO $300M (est $239.4M) - Sees Potential Approval Of Moderna's Fifth Product
11:18:29 AM UTC
SquawkNews
Moderna Q2 2026 Earnings

Rev. $145M (est $103.5M) - Loss/SHR $1.97 Vs.

Loss/SHR $2.13 Y/Y - Total Oper Expenses $960M (est $921.8M) - Cash & Cash Equivalents $1.72B (est $1.34B) - R&D Expenses $651M (est $671.7M) - Expects C55% Of H2 Rev To Be Recognized In Q3 - Sees FY Rev Growth Of 10% - Sees FY R&D Expenses About $2.9B, Saw About $3B - Still Sees FY CAPEX $200M TO $300M (est $239.4M) - Sees Potential Approval Of Moderna's Fifth Product